论文部分内容阅读
阿兹海默病疫苗CAD106在一期临床试验中表现良好,但尚需进一步的临床试验来证实其疗效。概述:阿兹海默病是一种极为常见的老年神经退行性疾病,或名老年痴呆,全世界有近2700万名患者。根据世界卫生组织的描述,老年痴呆是当下全球流行速度增长最快的疾病。目前,阿兹海默病无药可治,只有一些暂时性缓解症状的方法。科学家们正沿着几条不同的路径去寻找对付阿兹海默病的办法,其中治疗性疫苗是目前最流行的策略。大约十年前,就有了关于阿兹海默病疫苗的第一次研究。但那个候选疫苗不良反应过多,研究被迫中
Alzheimer’s disease vaccine CAD106 performed well in Phase I clinical trials, but further clinical trials are needed to confirm its efficacy. Summary: Alzheimer’s disease is a very common form of senile neurodegenerative disease, or Alzheimer’s disease, with nearly 27 million patients worldwide. According to the World Health Organization, dementia is the fastest-growing disease in the world today. Currently, Alzheimer’s disease is incurable and has only a few temporary ways to relieve the symptoms. Scientists are looking for ways to deal with Alzheimer’s disease along several separate routes, of which therapeutic vaccines are the most popular strategy. About a decade ago, there was the first study on Alzheimer’s disease. But too much of the candidate vaccine adverse reactions, the study was forced